123 related articles for article (PubMed ID: 21170881)
1. Fabry disease: perspectives of urinary proteomics.
Cuccurullo M; Beneduci A; Anand S; Mignani R; Cianciaruso B; Bachi A; Capasso G
J Nephrol; 2010; 23 Suppl 16():S199-212. PubMed ID: 21170881
[TBL] [Abstract][Full Text] [Related]
2. Early markers of Fabry disease revealed by proteomics.
Matafora V; Cuccurullo M; Beneduci A; Petrazzuolo O; Simeone A; Anastasio P; Mignani R; Feriozzi S; Pisani A; Comotti C; Bachi A; Capasso G
Mol Biosyst; 2015 Jun; 11(6):1543-51. PubMed ID: 25666440
[TBL] [Abstract][Full Text] [Related]
3. An easy and sensitive method for determination of globotriaosylceramide (Gb3) from urinary sediment: utility for Fabry disease diagnosis and treatment monitoring.
Rozenfeld PA; De Francesco NP; Borrajo GJ; Ceci R; Fossati CA
Clin Chim Acta; 2009 May; 403(1-2):194-7. PubMed ID: 19268437
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers of Fabry disease nephropathy.
Schiffmann R; Waldek S; Benigni A; Auray-Blais C
Clin J Am Soc Nephrol; 2010 Feb; 5(2):360-4. PubMed ID: 19965549
[TBL] [Abstract][Full Text] [Related]
5. Multiplex analysis of novel urinary lyso-Gb3-related biomarkers for Fabry disease by tandem mass spectrometry.
Lavoie P; Boutin M; Auray-Blais C
Anal Chem; 2013 Feb; 85(3):1743-52. PubMed ID: 23248976
[TBL] [Abstract][Full Text] [Related]
6. Enzyme replacement therapy for Fabry disease: morphologic and histochemical changes in the urinary sediments.
Utsumi K; Mitsuhashi F; Asahi K; Sakurazawa M; Arii K; Komaba Y; Katsumata T; Katsura K; Kase R; Katayama Y
Clin Chim Acta; 2005 Oct; 360(1-2):103-7. PubMed ID: 16112661
[TBL] [Abstract][Full Text] [Related]
7. Tissue and plasma globotriaosylsphingosine could be a biomarker for assessing enzyme replacement therapy for Fabry disease.
Togawa T; Kawashima I; Kodama T; Tsukimura T; Suzuki T; Fukushige T; Kanekura T; Sakuraba H
Biochem Biophys Res Commun; 2010 Sep; 399(4):716-20. PubMed ID: 20692233
[TBL] [Abstract][Full Text] [Related]
8. A metabolomic study to identify new globotriaosylceramide-related biomarkers in the plasma of Fabry disease patients.
Manwaring V; Boutin M; Auray-Blais C
Anal Chem; 2013 Oct; 85(19):9039-48. PubMed ID: 23968398
[TBL] [Abstract][Full Text] [Related]
9. Fabry disease: a review of current management strategies.
Mehta A; Beck M; Eyskens F; Feliciani C; Kantola I; Ramaswami U; Rolfs A; Rivera A; Waldek S; Germain DP
QJM; 2010 Sep; 103(9):641-59. PubMed ID: 20660166
[TBL] [Abstract][Full Text] [Related]
10. The identification of new biomarkers for identifying and monitoring kidney disease and their translation into a rapid mass spectrometry-based test: evidence of presymptomatic kidney disease in pediatric Fabry and type-I diabetic patients.
Manwaring V; Heywood WE; Clayton R; Lachmann RH; Keutzer J; Hindmarsh P; Winchester B; Heales S; Mills K
J Proteome Res; 2013 May; 12(5):2013-21. PubMed ID: 23464927
[TBL] [Abstract][Full Text] [Related]
11. [Anderson-Fabry disease].
Kes P; Basić-Jukić N; Brunetta B; Jurić I
Acta Med Croatica; 2006; 60(1):55-8. PubMed ID: 16802573
[TBL] [Abstract][Full Text] [Related]
12. Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy.
Breunig F; Wanner C
J Nephrol; 2008; 21(1):32-7. PubMed ID: 18264934
[TBL] [Abstract][Full Text] [Related]
13. Urinary total globotriaosylceramide and isoforms to identify women with Fabry disease: a diagnostic test study.
Paschke E; Fauler G; Winkler H; Schlagenhauf A; Plecko B; Erwa W; Breunig F; Urban W; Vujkovac B; Sunder-Plassmann G; Kotanko P
Am J Kidney Dis; 2011 May; 57(5):673-81. PubMed ID: 21186071
[TBL] [Abstract][Full Text] [Related]
14. Study of urinary proteomes in Anderson-Fabry disease.
Vojtová L; Zima T; Tesař V; Michalová J; Přikryl P; Dostálová G; Linhart A
Ren Fail; 2010; 32(10):1202-9. PubMed ID: 20954982
[TBL] [Abstract][Full Text] [Related]
15. Fabry disease: treatment and diagnosis.
Rozenfeld PA
IUBMB Life; 2009 Nov; 61(11):1043-50. PubMed ID: 19859978
[TBL] [Abstract][Full Text] [Related]
16. Urinary globotriaosylsphingosine-related biomarkers for Fabry disease targeted by metabolomics.
Auray-Blais C; Boutin M; Gagnon R; Dupont FO; Lavoie P; Clarke JT
Anal Chem; 2012 Mar; 84(6):2745-53. PubMed ID: 22309310
[TBL] [Abstract][Full Text] [Related]
17. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.
Hughes DA; Elliott PM; Shah J; Zuckerman J; Coghlan G; Brookes J; Mehta AB
Heart; 2008 Feb; 94(2):153-8. PubMed ID: 17483124
[TBL] [Abstract][Full Text] [Related]
18. Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice.
Jung SC; Han IP; Limaye A; Xu R; Gelderman MP; Zerfas P; Tirumalai K; Murray GJ; During MJ; Brady RO; Qasba P
Proc Natl Acad Sci U S A; 2001 Feb; 98(5):2676-81. PubMed ID: 11226298
[TBL] [Abstract][Full Text] [Related]
19. Alteration of proteomic profiles in PBMC isolated from patients with Fabry disease: preliminary findings.
Cigna D; D'Anna C; Zizzo C; Francofonte D; Sorrentino I; Colomba P; Albeggiani G; Armini A; Bianchi L; Bini L; Duro G
Mol Biosyst; 2013 Jun; 9(6):1162-8. PubMed ID: 23385635
[TBL] [Abstract][Full Text] [Related]
20. Cardiac challenges in patients with Fabry disease.
Weidemann F; Linhart A; Monserrat L; Strotmann J
Int J Cardiol; 2010 May; 141(1):3-10. PubMed ID: 19720409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
